EAM
UTHR icon

Exome Asset Management’s United Therapeutics UTHR Stock Holding History

Exome Asset Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.18M Sell
7,053
-632
-8% -$315K 2.16% 15
2025
Q4 		$3.74M Buy
7,685
+1,040
+16% +$484K 1.79% 16
2025
Q3 		$2.79M Buy
+6,645
New +$2.23M 1.69% 23

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Exome Asset Management's UTHR Position: Q1 2026 in Review

Exome Asset Management reduced its United Therapeutics (UTHR) stake by 8.2% in Q1 2026, selling an estimated $315K and leaving 7,053 shares worth $4.18M. The position accounts for 2.16% of the portfolio, ranked #15.

Exome Asset Management first reported a position in UTHR in Q3 2025 and has held it in 3 quarters since. 850 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.

  • Exome Asset Management held 7,053 shares of United Therapeutics worth $4.18M as of Q1 2026.
  • Exome Asset Management sold 632 United Therapeutics shares in Q1 2026, an estimated $315K.
  • United Therapeutics made up 2.16% of Exome Asset Management's portfolio in Q1 2026, its #15 holding.
  • Exome Asset Management first reported a position in United Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 850 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.

Based on Exome Asset Management's 13F filing for Q1 2026, filed 15 May 2026.